Results 181 to 190 of about 3,168 (197)

Romosozumab in Postmenopausal Women with Osteopenia

New England Journal of Medicine, 2014
Evenepoel, Pieter, d' Haese, Patrick, Brandenburg, Vincent   +2 more
openaire   +4 more sources

Romosozumab: a Review of Efficacy, Safety, and Cardiovascular Risk

Current Osteoporosis Reports, 2021
Cy W Fixen
exaly  

Romosozumab/teriparatide

Reactions Weekly, 2023
openaire   +1 more source

Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study

Journal of Bone and Mineral Research, 2018
Michael R Mcclung, Jacques P Brown, Adolfo Diez-Perez   +2 more
exaly  

Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis

Bone, 2020
Fang Lv, Xiaoling Cai, Wenjia Yang
exaly  

Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture

Regulatory Toxicology and Pharmacology, 2020
Aimee M Deaton, Gabrielle Boyd, Aurore Varela   +2 more
exaly  

Romosozumab Treatment in Postmenopausal Osteoporosis

New England Journal of Medicine, 2017
Felicia, Cosman, Daria B, Crittenden, Andreas, Grauer   +2 more
openaire   +6 more sources

Romosozumab: A first-in-class sclerostin inhibitor for osteoporosis

American Journal of Health-System Pharmacy, 2020
exaly  

Romosozumab-aqqg, upadacitinib, and risankizumab-rzaa

Journal of the American Pharmacists Association, 2019
Daniel A, Hussar, Haley E, Helms
openaire   +2 more sources

Romosozumab/Teriparatide

Reactions Weekly
openaire   +2 more sources